Validation of test technologies for the novel coronavirus at the National Institute of Virology (NIV), Pune, may take some months. While multiple technologies are being validated, the institute is not sharing positive control samples of the isolated virus with private players.
Positive controls are primarily derived from samples of Covid-19 patients and are noninfectious portions of the virus genome made synthetically. “Positive controls can also be imported, but currently there is a worldwide shortage . Hence, we have to depend on NIV and are working along with them,” a private player said. GSK Velu, Chairman of Trivitron Healthcare, which is validating domestic test kits with NIV, said the government body is not sharing them as they want to control testing.
You can read upto 3 premium stories before you subscribe to Magzter GOLD
Log-in, if you are already a subscriber
Get unlimited access to thousands of curated premium stories and 5,000+ magazines
READ THE ENTIRE ISSUE
March 21, 2020